Transatlantique Private Wealth LLC trimmed its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 20.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 19,396 shares of the biopharmaceutical company’s stock after selling 5,124 shares during the quarter. Transatlantique Private Wealth LLC’s holdings in Bristol-Myers Squibb were worth $800,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. ESL Trust Services LLC purchased a new stake in shares of Bristol-Myers Squibb in the 1st quarter worth $27,000. LGT Financial Advisors LLC increased its position in Bristol-Myers Squibb by 42.7% in the second quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 227 shares in the last quarter. MFA Wealth Advisors LLC bought a new position in shares of Bristol-Myers Squibb in the second quarter worth about $39,000. Fairman Group LLC purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at about $42,000. Finally, Beach Investment Counsel Inc. PA bought a new position in shares of Bristol-Myers Squibb during the 2nd quarter valued at approximately $42,000. 76.41% of the stock is owned by hedge funds and other institutional investors.
Bristol-Myers Squibb Price Performance
NYSE:BMY opened at $49.38 on Friday. The firm has a market capitalization of $100.10 billion, a price-to-earnings ratio of -15.93, a PEG ratio of 12.59 and a beta of 0.46. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.16 and a quick ratio of 1.02. The business has a 50 day simple moving average of $47.68 and a 200-day simple moving average of $46.49. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $59.46.
Bristol-Myers Squibb Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Investors of record on Friday, October 4th will be issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 4.86%. The ex-dividend date of this dividend is Friday, October 4th. Bristol-Myers Squibb’s payout ratio is currently -77.42%.
Analysts Set New Price Targets
A number of equities research analysts have commented on the stock. Barclays raised their target price on shares of Bristol-Myers Squibb from $41.00 to $42.00 and gave the stock an “underweight” rating in a research note on Thursday, August 22nd. Cantor Fitzgerald restated a “neutral” rating and set a $50.00 target price on shares of Bristol-Myers Squibb in a research note on Monday, September 16th. Deutsche Bank Aktiengesellschaft cut their price target on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research note on Tuesday, July 23rd. Jefferies Financial Group boosted their price target on Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a report on Wednesday, August 28th. Finally, StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Monday, July 29th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $55.00.
View Our Latest Stock Report on BMY
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Read More
- Five stocks we like better than Bristol-Myers Squibb
- Market Cap Calculator: How to Calculate Market Cap
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- What is Put Option Volume?
- MarketBeat Week in Review – 9/16 – 9/20
- P/E Ratio Calculation: How to Assess Stocks
- Don’t Miss These 3 Retail Stocks for Fall Gains
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.